Malaysia
Search
Sign In
Change Password
Points
Sign Out
Multidisciplinary
Top Medical News
Prophylaxis with proton pump inhibitors (PPI) can potentially avert mediastinal lesions associated with pulmonary vein isolation (PVI) among atrial fibrillation patients with pre-existing reflux oesophagitis, a recent study has shown.
Patients hospitalized for COVID-19 may experience after-effects of the condition 3 months post-discharge, according to a study from The Netherlands.
Living in neighbourhoods with liberal sidewalk coverage contributes to a lower incidence of dementia in urban areas, a study from Japan has found.
Patients with systemic sclerosis (SSc) are more likely to experience moderate-to-severe mitral regurgitation (MR) and aortic stenosis (AS) than age-matched non-SSc controls with similar cardiovascular (CV) comorbidities, results of a case-control study have shown.
Researchers have recently developed an interactive tool that quickly and accurately provides the probability of a novel coronavirus disease (COVID-19) patient’s progression to severe illness or death based on readily available clinical information.
Patients with rheumatoid arthritis (RA) have lower insulin resistance (IR) sensitivity and higher β cell function than those with systemic lupus erythematosus (SLE), reveals a study.
Both physical activity and sedentary time need to be taken into consideration when managing body weight among patients with type 2 diabetes (T2D), reports a new Japan study.
Special Reports
Primary immunodeficiency disease (PIDD) and allergies are two groups of conditions related to the immune system. However, they are uniquely different in terms of symptoms and treatment.
Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas.
Significant advancements in the treatment of acute lymphocytic leukaemia (ALL) in children have improved their outcomes. However, ALL treatment and eradication remain a major challenge in adults. In a recent webinar, two specialists from the US discussed current ALL treatment strategies and goals of future regimens.
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
At the recent Mylan (a Viatris company) webinar ‘Find the Missing Millions: Advanced Treatments for Hepatitis, ’panelists Prof Dr Rosmawati Mohamed, consultant gastroenterologist and hepatologist at University Malaya Medical Centre, and Prof Dr Henry Chan, director of the Chinese University of Hong Kong’s Center of Liver Health, discussed the current challenges in reducing the impact of chronic hepatitis B and C, as well as the evidence supporting new antivirals in treatment guidelines.
In an interview, Dr Eric Lee Kim Hor, a consultant paediatrician from Pantai Hospital Kuala Lumpur, spoke on the importance of vaccination in the prevention of influenza among children, resulting in the prevention of coinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) resulting in coronavirus disease (COVID-19) as well as reduction of burden on the healthcare system.
At the Nimenrix Speaker Training Workshop webinar, Dr Amgad Gamil of Pfizer Inc. discussed updates on the epidemiology of invasive meningococcal disease (IMD), while simultaneously reviewing the latest immunogenicity and safety data of the MenACWY-TT vaccine (Nimenrix®, Pfizer) in the paediatric population.
Conference Reports
The combination therapy of lenvatinib plus pembrolizumab significantly improves survival outcomes compared with the standard-of-care treatment of sunitinib in the first-line setting for advanced renal cell carcinoma (RCC), according to the CLEAR* study presented at the 2021 ASCO GU Cancer Symposium.
Treatment with the PD-1 immune checkpoint inhibitor nivolumab after radical surgery significantly extends disease-free survival (DFS) compared with placebo in patients with muscle-invasive urothelial carcinoma (MIUC) at high risk of recurrence, regardless of their PD-L1 status, according to the CheckMate 274 study presented at the 2021 ASCO GUCS.
In the extended follow-up of the phase III CheckMate 9ER trial, nivolumab + cabozantinib (NIVO+CABO) continued to fare better than sunitinib for the treatment of advanced renal cell carcinoma (aRCC), regardless of sarcomatoid (sRCC) status.
Long-term follow-up of the KEYNOTE-240* trial showed that improvements in overall survival (OS) and progression-free survival (PFS) with pembrolizumab were maintained in patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib, according to updated results of the trial presented at ASCO GI 2021.
Final analysis of the phase III TITAN* trial, presented at ASCO GU 2021, has shown that the addition of apalutamide to androgen deprivation therapy (ADT) improves overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC).
In patients with metastatic colorectal cancer (mCRC), the addition of anlotinib to best supportive care did not confer overall survival (OS) benefit, though there was improvement in progression-free survival (PFS), according to results of the phase III ALTER0703 trial presented at ASCO GI 2021.
Daily doses of baclofen may help reduce the risk of agitation among individuals with unhealthy alcohol use admitted to the intensive care unit (ICU), according to results of the BACLOREA* trial presented at eCCR 2021.
Multimedia
